Skip to content

JBIO JBIO Total debt

Total debt at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$15.58M-82.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$75.03M+37.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$13.61K-99.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.38M+29.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$36.83M+59.4%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $808K.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's total debt?
JBIO (JBIO) reported total debt of $808K in Q1 2026.
How has JBIO's total debt changed year-over-year?
JBIO's total debt increased by 159.0% year-over-year, from $312K to $808K.
What is the long-term trend for JBIO's total debt?
Over 4 years (2021 to 2025), JBIO's total debt has grown at a 10.3% compound annual growth rate (CAGR), from $574K to $851K.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.